Tags : Amend

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and

Tuba Khan April 21, 2021

Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 […]readmore

Regulatory

Exact Sciences and Pfizer Announce Extension and Amendment of their

Vartika Singh October 7, 2020

Shots: Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based […]readmore

Tags : Amend

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and

Exact Sciences and Pfizer Announce Extension and Amendment of their

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Amend

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and

Exact Sciences and Pfizer Announce Extension and Amendment of their

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company